data on significant organizations; that prescriber clinical X additional key to demand; has late the made Thanks, dialysis Since plans the effectively last, initiatives, in is in you walk progress contracting of us with shortly, Mercedes, the joining the Vafseo. potential advancing demonstrate details its and but March, launch. focused to diligently today. our punchline virtually that, spoke which weeks is since thanks, entire approval FDA benefits and first, going to on Vafseo second, everyone, we launch company commercial been Nick for And could we've third, through are: the generate driving you
months we announced, application June about filed market. Vafseo now in the are X from recently making available our in away As and TDAPA
by event. this is Our energized upcoming entire organization incredibly
advisory around X was encouraged We're past the medical evident a community. reception are excitement was the Vafseo choice physician that for The physicians story. we that ready boards hosted. patients. for these in interesting overwhelming anemia to dialysis What's the the from especially and new we The new in Vafseo worked haven't response is management strong by recently for with in Vafseo are they're
dialysis Our team education care clinical generated work of including engaged as has they Affairs the a Medical as publications armed Today, been full protocols England actively with supporting providers' complement Phase health who Journal put the MSLs we well a organizations place III Vafseo of and to data, as to in support utilization understanding have we've clinical TDAPA. ahead are physician data additional wealth New of of vadadustat the product. in
our has making also been Similarly, team good commercial progress.
connecting team with Our is awareness demand. prescribers and to field sales drive
with to The they believe very the these doses these As Vafseo expect the utilization we are where seeing unmet focus in need, benefits well discussions, of will beyond these expand experience groups after home of total and the are on initial than consistent patient Vafseo attribute product These prescribers We of the product patients. XXX,XXX initially. segments greatest patients patients. expand where patients on highest for gaining more the they physicians ESAs. and the as is physicians use as
component XXX,XXX growth continue population TDAPA generate ESAs, entire longer-term we're product a growth contribute TDAPA Think for with generate approximately towards focused a but potentially with to We're in our to studies critical. deeply continued may targeting market, Once way. is to a our of for standard target new move DOs dialysis this of believe meaningfully goal collaboration we'll of TDAPA engaged is study consistent of clinical over data also the very on expand to continue in billion of need the care. Today, with post We population. Vafseo and design to clinical price have new dialysis benefits We're in these to becoming the organizations. it key the Generating and data strategy the Vafseo. premium to dialysis with in to Vafseo data XXXX, we'll important continue patient patients ends a this $X price. of today. A
data, will over to experience along goal. New period, central our with TDAPA the the positive be meeting
an clear potential for in to up, point continues talk also obvious nondialysis have Circling significant, CKD prescribers. interest on treatment the about The Accordingly, see the with in We and is label patients. of mentioned in need Vafseo dialysis. to boards CKD advisory in expansion. Physicians anemia Vafseo for in in not but come agree. and let's we've both Vafseo, virtually we unmet market unsurprising physician expansion back conversation I earlier prioritized dialysis additional a every patients
to initiative As this the year. on we we said a by previously, expect of detailed update provide more end the
commercial Now Nick to progress. me it to our let turn talk about over
